SANTA MONICA, Calif., Nov. 6, 2018 /PRNewswire/ -- Today, the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) published guidelines on the diagnosis and treatment of bradycardia, an abnormally slow heart rate, along with the supporting systematic review. The 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay were simultaneously published in Circulation, the Journal of the American College of Cardiology (JACC), and HeartRhythm. An Executive Summary was also published in all three journals: Circulation, JACC, and HeartRhythm.
Doctor Evidence, a software and services technology company that finds, categorizes, and synthesizes data from published sources, conducted the underlying systematic review of the clinical evidence used by the American College of Cardiology/American Heart Association/Heart Rhythm Society Evidence Review Committee. The Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay was co-published in Circulation, JACC, and HeartRhythm.
The joint Evidence Review Committee, chaired by David J Slotwiner, MD, Assistant Professor of Clinical Medicine at Weill Cornell Medical College, worked closely with Doctor Evidence teams for the comprehensive and systematic search and rigorous analyses. In addition to the innovative technology platforms, Doctor Evidence provided methodology, library, data integrity, ontology management, and other services to ensure the high quality of this evidence review.
The ACC/AHA/HRS jointly developed guidelines, written by a 19-member committee chaired by Fred M. Kusumoto, MD, FACC, FAHA, FHRS, relied on the results of the evidence review and analyses. The important recommendations in these guidelines will inform the diagnosis, treatment, and care of patients experiencing very slow heart rates.
During the 2018 AHA Scientific Sessions, November 10-12, 2018 in Chicago, Illinois, a moderated panel will be devoted to presentation of the new content in these guidelines. "EA.CVS.1321 - The 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: What Do You Need To Know?" will be convened November 11, 2018 from 2:00 PM – 3:15 PM Central at McCormick Place South Building, room S105abc.
"We are proud to have worked closely with the guideline development teams from the ACC, AHA, and HRS to bring evidence-informed recommendations to patients and cardiologists," stated Robert Battista, CEO and co-founder of Doctor Evidence. "The work of Doctor Evidence's GROWTH initiative facilitates evidence-based medicine and methods through similar collaborations with many other medical professional societies, medical centers, and academic researchers."
About Doctor Evidence and GROWTH
Doctor Evidence (DRE) is a health technology and consulting company utilizing state-of-the-art solutions that identify, synthesize, and analyze complex clinical research data into fit-to-purpose actionable knowledge. Resulting high quality evidence reviews provide guideline developers, academic researchers, medical providers, manufacturers, payers, and patients with evidence-based information to make timely and educated decisions on recommended treatment protocols, outcomes research, health economics, risk management, market access, reimbursement, value determinations, and burden of illness cost models. These methodologically rigorous reviews and analyses fully comply with accepted international standards to address the needs of patients, providers, and scientists worldwide. To learn more about Doctor Evidence, visit drevidence.com and GROWTHevidence.com.
SOURCE Doctor Evidence